NCT04356989View on ClinicalTrials.gov

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function

CompletedOBSERVATIONAL
Enrollment

493

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

November 15, 2022

Study Completion Date

January 16, 2023

Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT04356989 - Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function | Biotech Hunter | Biotech Hunter